Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Research Article

Potent Lipophilic Melatoninergic x-fluoro-y-methoxy Substituted Phenylalkylamides: Molecular Dynamics Calculations and in vitro Modified Release in Aqueous Media from Tablet Formulations

Author(s): Marilena Vlachou*, Angeliki Siamidi, Dionysia Anagnostopoulou, Chrystalla Protopapa, Rodoula Kompogennitaki, Aikaterini Sakellaropoulou, Natasa Efstathiou, Ioannis Papanastasiou, Maria Billia and Thomas Mavromoustakos

Volume 29, Issue 17, 2023

Published on: 12 June, 2023

Page: [1370 - 1378] Pages: 9

DOI: 10.2174/1381612829666230607093311

Price: $65

Abstract

Introduction: We report herein on the design and development of matrix tablets containing potent synthetic melatonin (MLT) receptor analogues, the x-fluoro-y-methoxy substitiuted phenylalkylamides (compounds I-IV), the preparation and melatoninergic potency of which was recently communicated.

Methods: The presence of the fluorine atom in compounds I-IV, besides not affecting their binding affinity, compared to the pineal hormone melatonin, it also slows down their metabolism, which is a major drawback of MLT. However, as fluorine increases the lipophilicity, solid pharmaceutical formulations of I-IV, involving the appropriate biopolymers for their modified release in aqueous media, were developed in the context of the present work.

Results: The release profile of analogues I-IV was found to be similar to that of MLT and also of the commercially available drug, Circadin®. Some of these systems are suitable for dealing with sleep onset problems, whilst others for dealing with combined sleep onset/sleep maintenance problems.

Conclusion: Apart from the nature and relevant content of the formulants used, this bimodal release profile of the new analogues depends, to a large extent, on the diverse structural arrangement of their side chains in space, as nicely demonstrated by the molecular dynamics calculations, conducted in the context of this study.

« Previous Next »
[1]
Arendt J. Melatonin and human rhythms. Chronobiol Int 2006; 23(1-2): 21-37.
[http://dx.doi.org/10.1080/07420520500464361] [PMID: 16687277]
[2]
Delagrange P, Guardiola-Lemaitre B. Melatonin, its receptors, and relationships with biological rhythm disorders. Clin Neuropharmacol 1997; 20(6): 482-510.
[http://dx.doi.org/10.1097/00002826-199712000-00002] [PMID: 9403224]
[3]
Reppart SM, Weaver DR, Godson C. Melatonin receptors step into the light: Cloning and classification of subtypes. Trends Pharmacol Sci 1996; 17(3): 100-2.
[http://dx.doi.org/10.1016/0165-6147(96)10005-5] [PMID: 8936344]
[4]
Crupi R, Mazzon E, Marino A, et al. Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice. J Pineal Res 2010; 49(2): no.
[http://dx.doi.org/10.1111/j.1600-079X.2010.00775.x] [PMID: 20536684]
[5]
Fusco R, Siracusa R, D’Amico R, et al. Melatonin plus folic acid treatment ameliorates reserpine-induced fibromyalgia: An evaluation of pain, oxidative stress, and Inflammation. Antioxidants 2019; 8(12): 628.
[http://dx.doi.org/10.3390/antiox8120628] [PMID: 31817734]
[6]
Vlachou M, Siamidi A, Dedeloudi A, Konstantinidou S, Papanastasiou I. Pineal hormone melatonin as an adjuvant treatment for COVID-19. Int J Mol Med 2021; 47(4): 47.
[http://dx.doi.org/10.3892/ijmm.2021.4880] [PMID: 33576451]
[7]
Vlachou M, Kikionis S, Siamidi A, et al. Modified in vitro release of melatonin loaded in nanofibrous electrospun mats incorporated into monolayered and three-layered tablets. J Pharm Sci 2019; 108(2): 970-6.
[http://dx.doi.org/10.1016/j.xphs.2018.09.035] [PMID: 30312723]
[8]
Vlachou M, Siamidi A, Goula E, et al. Probing the release of the chronobiotic hormone melatonin from hybrid calcium alginate hydrogel beads. Acta Pharm 2020; 70(4): 527-38.
[http://dx.doi.org/10.2478/acph-2020-0037] [PMID: 32412433]
[9]
Vlachou M, Tragou K, Siamidi A, et al. Modified in vitro release of the chronobiotic hormone melatonin from matrix tablets based on the marine sulfated polysaccharide ulvan. J Drug Deliv Sci Technol 2018; 44: 41-8.
[http://dx.doi.org/10.1016/j.jddst.2017.11.019]
[10]
Vlachou M, Ioannidou V, Vertzoni M, Tsotinis A, Afroudakis P, Sugden D. Controlled release from solid pharmaceutical formulations of two N-alkanoyl-4-methoxybicyclo[4.2.0]octa-1,3,5-trien- 7-ethanamines with melatoninergic activity. LDDD 2015; 12: 259-62.
[http://dx.doi.org/10.2174/1570180811666141024005226]
[11]
Tsotinis A, Kompogennitaki R, Papanastasiou I, Garratt PJ, Bocianowska A, Sugden D. Fluorine substituted methoxyphenylalkyl amides as potent melatonin receptor agonists. MedChemComm 2019; 10(3): 460-4.
[http://dx.doi.org/10.1039/C8MD00604K] [PMID: 31191854]
[12]
Georgiou N, Gouleni N, Chontzopoulou E, et al. Structure assignment, conformational properties and discovery of potential targets of the Ugi cinnamic adduct NGI25. J Biomol Struct Dyn 2021; 41(4): 1253-66.
[PMID: 34963425]
[13]
Podczeck F. Comparison of in vitro dissolution profiles by calculating mean dissolution time (MDT) or mean residence time (MRT). Int J Pharm 1993; 97(1-3): 93-100.
[http://dx.doi.org/10.1016/0378-5173(93)90129-4]
[14]
Rinaki E, Dokoumetzidis A, Macheras P. The mean dissolution time depends on the dose/solubility ratio. Pharm Res 2003; 20(3): 406-8.
[http://dx.doi.org/10.1023/A:1022652004114] [PMID: 12669960]
[15]
Khan KA. The concept of dissolution efficiency. J Pharm Pharmacol 2011; 27(1): 48-9.
[http://dx.doi.org/10.1111/j.2042-7158.1975.tb09378.x] [PMID: 235616]
[16]
Ritger PL, Peppas NA. A simple equation for description of solute release I. Fickian and non-fickian release from non-swellable devices in the form of slabs, spheres, cylinders or discs. J Control Release 1987; 5(1): 23-36.
[http://dx.doi.org/10.1016/0168-3659(87)90034-4]
[17]
Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm 1983; 15(1): 25-35.
[http://dx.doi.org/10.1016/0378-5173(83)90064-9]
[18]
Peppas NA, Sahlin JJ. A simple equation for the description of solute release. III. Coupling of diffusion and relaxation. Int J Pharm 1989; 57(2): 169-72.
[http://dx.doi.org/10.1016/0378-5173(89)90306-2]
[19]
Jain AK, Söderlind E, Viridén A, et al. The influence of hydroxypropyl methylcellulose (HPMC) molecular weight, concentration and effect of food on in vivo erosion behavior of HPMC matrix tablets. J Control Release 2014; 187: 50-8.
[http://dx.doi.org/10.1016/j.jconrel.2014.04.058] [PMID: 24818771]
[20]
Vlachou M, Siamidi A, Anagnostopoulou D, Christodoulou E, Bikiaris ND. Modified release of the pineal hormone melatonin from matrix tablets containing Poly(L-lactic acid) and its PLA- co-PEAd and PLA-co-PBAd copolymers. Polymers 2022; 14(8): 1504.
[http://dx.doi.org/10.3390/polym14081504] [PMID: 35458252]
[21]
Suzuki S, Green PG, Bumgarner RE, Dasgupta S, Goddard WA III, Blake GA. Benzene forms hydrogen bonds with water. Science 1992; 257(5072): 942-5.
[http://dx.doi.org/10.1126/science.257.5072.942] [PMID: 17789637]

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy